Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

Background Preclinical evidence suggests that cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors enhance antitumor immunity. We conducted a phase I trial of ribociclib (CDK4/6 inhibitor) plus spartalizumab (PD-1 inhibitor) in patients with hormone receptor (HR)-positive/HER2-negative metastatic br...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sara M Tolaney, Tianyu Li, Elizabeth A Mittendorf, Geoffrey I Shapiro, Stephanie K Dougan, Nabihah Tayob, Joyce F Liu, Khanh Do, Heather Parsons, Molly DiLullo, Eileen Wrabel, Lestat R Ali, Ana C Garrido-Castro, Noah Graham, Christina Herold, Jennifer Desrosiers, Shom Goel, Amy J Williams
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-02-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/2/e010430.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors
by: Aurora Norman, et al.
Published: (2025-01-01)

Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer
by: Corti C, et al.
Published: (2025-04-01)

Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality
by: N. A. Avxentyev, et al.
Published: (2025-05-01)

Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
by: Mohammed Hawash
Published: (2024-10-01)

Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice
by: Manoela Manova, et al.
Published: (2023-03-01)

An immunological mechanism of resistance to CDK4/6 inhibitors in HR+ breast cancer
by: Claudia Galassi, et al.
Published: (2025-12-01)

Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
by: Ioannis A. Voutsadakis
Published: (2025-06-01)

Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
by: Lisa M Butler, et al.
Published: (2020-01-01)

Insulin-like growth factor-binding protein-3 is induced by tamoxifen and fulvestrant and modulates fulvestrant response in breast cancer cells
by: Keenan L. Flynn, et al.
Published: (2024-11-01)

ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT
by: J.F.R. Robertson, et al.
Published: (2014-09-01)

Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era
by: LI Bin, TAO Zhonghua, HU Xichun
Published: (2025-03-01)

Dynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients
by: Xiaopeng Sun, et al.
Published: (2025-07-01)

Efficacy and safety of PI3K inhibitors combined with fulvestrant for HR+/HER2− advanced breast cancer: a systematic review and meta-analysis
by: Xuefeng Li, et al.
Published: (2025-06-01)

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
by: Carlos M Roggero, et al.
Published: (2025-02-01)

Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer
by: Hyunwook Kim, et al.
Published: (2025-02-01)

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)
by: Laura M. Spring, et al.
Published: (2025-01-01)

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01)

CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment
by: Tong Gao, et al.
Published: (2025-05-01)

In silico identification of novel CDK4 inhibitors for retinoblastoma
by: Mukesh kumar, et al.
Published: (2024-12-01)

The Effect of Proton Pump Inhibitors on Metastatic Breast Cancer in Patients Treated with CDK4/6i
by: Mohamed Khalifa, et al.
Published: (2025-04-01)

Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer
by: Marya Hussain, et al.
Published: (2025-03-01)

Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2− advanced breast cancer: Final results of the randomized phase III MONARCH plus trial
by: Xichun Hu, et al.
Published: (2025-06-01)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
by: Marta Buzzetti, et al.
Published: (2021-03-01)

Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy
by: Stefanos Ioannis Moukas, et al.
Published: (2025-03-01)

Reevaluating prognostic differences in HR+/HER2− Breast Cancer: The unaccounted impact of CDK4/6 inhibitors
by: Arif Hakan Önder
Published: (2025-06-01)

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
by: Roberta Scafetta, et al.
Published: (2025-08-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
by: Charlotte K. Kindt, et al.
Published: (2025-01-01)

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
by: Sheelagh Frame, et al.
Published: (2020-01-01)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
by: Efthymia Skafida, et al.
Published: (2023-01-01)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
by: Jeffrey Schlom, et al.
Published: (2023-09-01)

Olomoucine II, New Effective CDK Inhibitor with Strong Cytotoxic Properties
by: R. Lenobel, et al.
Published: (2001-01-01)

Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
by: Eudald Felip, et al.
Published: (2025-08-01)

Identification of new inhibitors of the kinase activity of CDK2 and CDK9 by molecular modeling and high-efficiency screening
by: G.V. Andrianov, et al.
Published: (2021-12-01)

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
by: Romualdo Barroso-Sousa, et al.
Published: (2025-05-01)

Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E)
by: Md Mohiuddin, et al.
Published: (2025-08-01)

Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China
by: Caifeng Jia, et al.
Published: (2025-04-01)

Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines
by: Ilenia Migliaccio, et al.
Published: (2025-07-01)

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
by: R. C. Coombes, et al.
Published: (2023-07-01)

Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2− metastatic breast cancer: clinical and molecular perspectives
by: Jessé Lopes da Silva, et al.
Published: (2025-07-01)